EZH2 seems to act as a tumor suppressor in MPN, and a high number of loss of function mutations have been identified that synergizes with JAK2V617F in initiating MPN and promoting myelofibrosis [61]. This evidence concerns the gene EZH2 and myeloproliferative neoplasm.